|
| View:
Latest News | Top Stories |
|
| 1.
|
Warner Chilcott Near Buy Point In Its Pattern
-
Investor's Business Daily
-
Mon 6:40 pm ET
Ireland-based drug developer Warner Chilcott has formed a base-on-base pattern.
|
|
| 2.
|
The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635
-
Marketwire
-
Mon 6:00 pm ET
|
|
| 3.
|
SciClone Announces Commencement and Complete Enrollment of Clinical Study Examining ZADAXIN's Ability to Enhance the H1N1 Vaccine Led by European Partner, Sigma-Tau
-
Marketwire
-
Mon 4:05 pm ET
|
|
| 4.
|
Allos Therapeutics Announces Issuance of U.S. Patent for FOLOTYN
-
Business Wire
-
Mon 8:00 am ET
WESTMINSTER, Colo.----Allos Therapeutics, Inc. today announced that the United States Patent and Trademark Office has issued a patent for the use of FOLOTYN™ for the treatment of T-cell lymphoma. U.S.
|
|
| 5.
|
Gentium Reports Third Quarter Financial Results; Provides Financial Update
-
Business Wire
-
Mon 7:00 am ET
VILLA GUARDIA , Italy----Gentium S.p.A. today reported financial results for the quarter ended September 30, 2009.
|
|
| 6.
|
Encouraging Results for Cumberland
-
Zacks.com
-
Fri Nov 27
Caldolor , the first injectable product available in the U.S.reduced fever in burn patients over the first 24 hours of treatment.
|
|
| 7.
|
Sucampo Announces Lubiprostone Data Presented at GASTRO 2009 UEGF/WCOG
-
Business Wire
-
Wed Nov 25
BETHESDA, Md.----Sucampo Pharma Europe, Ltd., and Sucampo Pharma Americas, Inc., subsidiaries of Sucampo Pharmaceuticals, Inc. , today presented additional clinical data for lubiprostone at GASTRO 2009 UEGF/WCOG, the joint meeting of the United European Gastroenterology Federation , the World Gastroenterology Organisation , the World Organisation of Digestive Endoscopy and the British Society of Gastroenterology , in London.
|
|
| 8.
|
Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
PR Newswire
-
Tue Nov 24
Orexigen® Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity, today announced that on November 18, 2009 the Compensation Committee of the Company's Board of Directors granted an inducement stock option to purchase 200,000 shares of common stock to Preston Klassen, M.D., its newly appointed Head of the Global Contrave Program.
|
|
| 9.
|
Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders
-
PR Newswire
-
Mon Nov 23
-
|
|
| 10.
|
Somaxon Pharmaceuticals Reports 2009 Third Quarter Financial Results
-
Business Wire
-
Thu Nov 5
SAN DIEGO----Somaxon Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced financial results for the third quarter ended September 30, 2009.
|
|
